Literature DB >> 8033138

Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

S Ganesh1, C F Sier, G Griffioen, H J Vloedgraven, A de Boer, K Welvaart, C J van de Velde, J H van Krieken, J H Verheijen, C B Lamers.   

Abstract

Human colorectal carcinogenesis has been shown previously to be associated with impressive changes in the tissue levels of plasminogen activators and their inhibitors, exemplified by an increase in the urokinase-type plasminogen activator (u-PA) and the inhibitors PAI-1 and PAI-2, and a decrease in tissue-type plasminogen activator (t-PA). In the present study we evaluated the prognostic significance of these parameters to the overall survival of patients with colorectal cancer, in conjunction with several major clinicopathological parameters like age, gender, differentiation grade, and Dukes' stage. Univariate analyses revealed that a low t-PA antigen level, low t-PA activity, and high u-PA/t-PA antigen ratio in normal mucosa and a high u-PA and PAI-2 antigen level in carcinomas are prognostic for a poor overall survival of patients with colorectal cancer. The prognostic value of t-PA antigen and activity in normal mucosa, the antigen ratio of u-PA in carcinoma (C) and t-PA in corresponding normal (N) mucosa [u-PA(C)/t-PA(N) antigen ratio], and PAI-2 antigen in carcinomas was found to be independent from clinicopathological parameters by multivariate analyses. These observations illustrate the clinical importance of the plasminogen activation cascade at the tissue level in colorectal cancer invasion, metastasis, and survival.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033138

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 2.  Cell surface molecules and their prognostic values in assessing colorectal carcinomas.

Authors:  J Haier; M Nasralla; G L Nicolson
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.

Authors:  Gabriel Scicolone; Viviana Sanchez; Liliana Vauthay; Federico Fuentes; Alejandro Scicolone; Lorenzo Scicolone; Melina Rapacioli; Vladimir Flores
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

4.  Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.

Authors:  G Xiao; Y E Liu; R Gentz; Q A Sang; J Ni; I D Goldberg; Y E Shi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

6.  Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

Authors:  H Shiomi; Y Eguchi; T Tani; M Kodama; T Hattori
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

8.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

9.  Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.

Authors:  George Van Buren; Michael J Gray; Nikolaos A Dallas; Ling Xia; Sherry J Lim; Fan Fan; Andrew P Mazar; Lee M Ellis
Journal:  Cancer       Date:  2009-07-15       Impact factor: 6.860

10.  Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.

Authors:  Khalid Bajou; Hongjun Peng; Walter E Laug; Catherine Maillard; Agnes Noel; Jean M Foidart; Joseph A Martial; Yves A DeClerck
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.